Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Refametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 6/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Refametinib SCHEMBL345334 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29385439 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29360059 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29358040 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL346872 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL10314890 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29398471 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29368551 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL16127640 | 0.94 | MAP2K1 (0.89) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL3691191 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| EP-3702445-B1 | NOVEL MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS INC (KR) | 2022-12-07 | — | — | EP | claimed |
| EP-3702445-A2 | NOVEL MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-09-02 | — | — | EP | claimed |
| EP-3643777-A1 | NOVEL MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL | Cellatoz Therapeutics, Inc. (KR) | 2020-04-29 | — | — | EP | claimed |
| US-10576106-B2 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2020-03-03 | — | — | US | claimed |
| US-20190247441-A1 | NOVEL MUSCULOSKELETAL STEM CELL AND MEDIUM FOR INDUCING DIFFERENTIATION OF MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS, INC. (KR) | 2019-08-15 | — | — | US | claimed |
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| EP-2405908-B1 | PHARMACEUTICAL COMBINATION OF RDEA119/BAY 869766 AND GEMCITABINE FOR THE TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | claimed |
| US-20120016034-A1 | Polymorphic Form Of N-(S)-(3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-6-Methoxyphenyl)-1-(2,3-Dihydroxypropyl)Cyclopropane-1-Sulfonamide And Uses Thereof | ARDEA BIOSCIENCES, INC. | 2012-01-19 | — | — | US | claimed |
| EP-2405907-A1 | TREATMENT OF PANCREATIC CANCER | Ardea Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | claimed |
| WO-2011128407-A9 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | claimed |
| US-8044240-B2 | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof | ARDEA BIOSCIENCES INC. (US) | 2011-10-25 | — | — | US | claimed |
| WO-2011128407-A2 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-20 | — | — | WO | claimed |
| WO-2011009541-A1 | PREPARATION OF (R)- AND (S)-N-(3, 4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)--6-METHOXYPHENYL) -1- (2, 3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND PROTECTED DERIVATIVES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2011-01-27 | — | — | WO | claimed |
| WO-2010105082-A1 | TREATMENT OF PANCREATIC CANCER | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | claimed |
| US-20090227681-A1 | POLYMORPHIC FORM OF N-(S)-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL) CYCLOPROPANE-1-SULFONAMIDE AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016034-A1 | Polymorphic Form Of N-(S)-(3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-6-Methoxyphenyl)-1-(2,3-Dihydroxypropyl)Cyclopropane-1-Sulfonamide And Uses Thereof | CYP2S1, CYP2D6, SULT2A1 | MAP2K1 4777/4885MAP2K2 4757/4885CHEK1 3683/4885 |
| US-20090227681-A1 | POLYMORPHIC FORM OF N-(S)-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL) CYCLOPROPANE-1-SULFONAMIDE AND USES THEREOF | CYP2S1, CYP2D6, SULT2A1 | MAP2K1 4765/4885MAP2K2 4747/4885CHEK1 3724/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | MAP2K1 7/4885MAP2K2 3/4885CHEK1 507/4885 |
| US-20240382484-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | PDPK1, PLK3, PLK2 | MAP2K1 207/4885MAP2K2 205/4885CHEK1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.